Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;174(4):411-422.
doi: 10.1111/imm.13889. Epub 2025 Jan 9.

Simultaneous Blockade of CD209 and CD209L by Monoclonal Antibody Does Not Provide Sufficient Protection Against Multiple Viral Infections In Vivo

Affiliations

Simultaneous Blockade of CD209 and CD209L by Monoclonal Antibody Does Not Provide Sufficient Protection Against Multiple Viral Infections In Vivo

Yanyun Du et al. Immunology. 2025 Apr.

Abstract

Many virus species, including Ebola virus, Marburg virus, SARS-CoV-2, dengue virus (DENV) and Zika virus (ZIKV), exploit CD209 and CD209L as alternative or attachment receptors for viral cis- or trans-infection. Thus, CD209 and CD209L may be critical targets for the development of therapeutic monoclonal blocking antibody drugs to disrupt the infection process caused by multiple viruses. Here, we produced a human chimeric monoclonal blocking antibody that simultaneously blocks CD209 and CD209L, namely 7-H7-B1. We show that 7-H7-B1 effectively blocks multiple pseudotyped or live viral infections in vitro, including SARS-CoV, SARS-CoV-2, Ebola virus, Marburg virus, ZIKV and DENV infections. However, the 7-H7-B1 mAb does not provide favourable protection against Zaire Ebola virus or ZIKV infection in hCD209 knock-in mice in vivo. Thus, our findings indicate that although CD209 and CD209L are critical for multiple viral infections in vitro, they may play only a partial role in viral infections in vivo.

Keywords: CD209 and CD209L; monoclonal antibody; viral infection.

PubMed Disclaimer

References

    1. E. J. Soilleux, R. Barten, and J. Trowsdale, “DC‐SIGN; a Related Gene, DC‐SIGNR; and CD23 Form a Cluster on 19p13,” Journal of Immunology 165 (2000): 2937–2942.
    1. D. A. Mitchell, A. J. Fadden, and K. Drickamer, “A Novel Mechanism of Carbohydrate Recognition by the C‐Type Lectins DC‐SIGN and DC‐SIGNR. Subunit Organization and Binding to Multivalent Ligands,” Journal of Biological Chemistry 276 (2001): 28939–28945.
    1. Y. Guo, H. Feinberg, E. Conroy, et al., “Structural Basis for Distinct Ligand‐Binding and Targeting Properties of the Receptors DC‐SIGN and DC‐SIGNR,” Nature Structural & Molecular Biology 11 (2004): 591–598.
    1. C. P. Alvarez, F. Lasala, J. Carrillo, O. Muñiz, A. L. Corbí, and R. Delgado, “C‐Type Lectins DC‐SIGN and L‐SIGN Mediate Cellular Entry by Ebola Virus in Cis and in Trans,” Journal of Virology 76 (2002): 6841–6844.
    1. A. Marzi, T. Gramberg, G. Simmons, et al., “DC‐SIGN and DC‐SIGNR Interact With the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome Coronavirus,” Journal of Virology 78 (2004): 12090–12095.

Publication types

MeSH terms

Associated data

LinkOut - more resources